Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-1708 · 1 trial · 1 indication
Blood samples will be collected to determine the AUC0-inf of MK-1708.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| Period 1: MK-1708 | EXPERIMENTAL | Participants will receive a single oral dose of MK-1708 on Day 1. |
| Period 2: MK-1708 and Itraconazole | EXPERIMENTAL | A washout period of at least 10 days will occur between MK-1708 dosing in Period 1 and the first itraconazole dosing in Period 2. In Period 2, participants will receive itraconazole twice daily on Day 1 and once daily on Days 2 through Day 19. Participants will also receive a single oral dose of MK-1708 on Day 4. |
| Name | Type | Description |
|---|---|---|
| MK-1708 | DRUG | Oral administration |
| Itraconazole | DRUG | Oral administration |
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health before randomization * Has a body mass index (BMI) ≥18.5 and ≤32 kg/m\^2, inclusive Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has...
Top 20 of 30 competitors
MK-1708 is an investigational small molecule drug being developed by Merck & Company, Inc. (MRK) for Alzheimer's disease. It is in Phase 1 clinical development and has been studied in a drug interaction trial in healthy participants. It is not approved for any indication.
MK-1708 is being studied for Alzheimer's disease, a neurological condition. The clinical work completed so far was a Phase 1 drug interaction study conducted in healthy adult participants rather than in patients with Alzheimer's disease, so its use in patients remains under investigation.
MK-1708 is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor of the clinical program for this asset.
MK-1708 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The program has not advanced beyond early-stage clinical testing, and the drug is investigational rather than approved.
MK-1708 has been evaluated in one completed Phase 1 trial, NCT06586606, titled a study to evaluate the effects of itraconazole on MK-1708 in healthy participants. It enrolled 12 participants in the United States and was a controlled study in healthy volunteers.
MK-1708 is not approved. It is an investigational small molecule in Phase 1 clinical development for Alzheimer's disease, and its only completed trial was a drug interaction study in healthy participants. Further clinical testing would be needed before any regulatory review.